Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein
N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe
The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.
bioRxiv · Jan 19, 2021Immunology